Biofrontera Resale Offering Signals Strategic Shift, Ameluz® Rights Acquired

TL;DR

**Biofrontera's full acquisition of Ameluz® US rights and Xepi® divestiture is a focused bet on PDT, but the earnout structure and reliance on a single product line introduce significant risk.**

AI Summary

Biofrontera Inc. (BFRIW) is offering 4,000,640 shares of common stock for resale by selling stockholders, converted from Series C Convertible Preferred Stock issued on October 24, 2025. The company will not receive any proceeds from this sale. Biofrontera's primary product, Ameluz®, a photodynamic therapy (PDT) for actinic keratoses (AK), is central to its strategy. Effective June 1, 2024, Biofrontera assumed control of all Ameluz® clinical trials in the US, aiming for cost management and efficiency. On October 20, 2025, Biofrontera acquired all US rights to Ameluz® and RhodoLED® from Biofrontera Group, replacing a transfer pricing model with an earnout of 12% of US revenues up to $65.0 million and 15% above that threshold. The company divested its Xepi® product line in Q4 2025 for a maximum of $10,000,000, including $3,000,000 cash upfront and potential earnouts of $3,000,000 each upon achieving $10,000,000 and $15,000,000 in annual net sales. Recent FDA approvals include the RhodoLED® XL lamp in late October 2021 and an increased Ameluz® dosage from one to three tubes per treatment in October 2024. A Supplemental New Drug Application for superficial basal cell carcinoma treatment with Ameluz® was submitted in November 2025.

Why It Matters

This S-1 filing signals a significant strategic pivot for Biofrontera, as it fully consolidates the US rights to its flagship Ameluz® product, moving away from a complex licensing structure to a direct earnout model. For investors, this could simplify revenue recognition and potentially improve margins, but the earnout structure ties future payments directly to Ameluz® sales performance. The divestiture of the Xepi® product line for up to $10 million allows the company to sharpen its focus on dermatological PDT, a market estimated at $4 billion, where it aims to expand its 2% share. Competitively, this move positions Biofrontera to more directly challenge rivals like Levulan® in the PDT space, while also targeting a larger share of the cryotherapy market for AKs.

Risk Assessment

Risk Level: high — The company faces high risk due to its heavy reliance on a single product, Ameluz®, and the associated PDT market, which currently constitutes only 2% of the total AK treatment market. The earnout agreement with Biofrontera Group, requiring 12-15% of US Ameluz® revenues, could significantly impact profitability. Furthermore, the company's common stock was trading at a low $0.81 on December 2, 2025, indicating market skepticism and potential delisting risk from Nasdaq.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Biofrontera's ability to significantly expand Ameluz® market share beyond its current 2% in the AK treatment space. Monitor sales growth closely, particularly against the $65.0 million earnout threshold, and assess the progress of clinical trials for label expansion. Consider the impact of potential dilution from the 4,000,640 shares being resold by selling stockholders.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

0%

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

0%

cash Position

$0

revenue Growth

+0%

Key Numbers

• 4,000,640 — Shares of Common Stock (Offered for resale by Selling Stockholders, converted from Series C Preferred Stock.)
• $0.81 — Last Reported Sale Price (Per share of common stock on December 2, 2025, indicating low valuation.)
• 12% — Earnout Percentage (Of US Ameluz® revenues when net sales are $65.0 million or less, payable to Biofrontera Group.)
• 15% — Earnout Percentage (Of US Ameluz® revenues when net sales exceed $65.0 million, payable to Biofrontera Group.)
• $10,000,000 — Maximum Purchase Price (For the divestiture of the Xepi® product line to Pelthos Therapeutics Inc.)
• $3,000,000 — Cash Payment (Received on the Closing Date for the Xepi® Transaction.)
• 91% — Clearance Rate (Of AKs after one or two Ameluz® PDT treatments.)
• 58,000,000 — Americans Affected (By Actinic Keratoses (AKs).)
• 2% — PDT Market Share (Current market share for Photodynamic Therapy in the AK treatment market.)
• $500,000,000 — Targeted Market Size (For Ameluz® PDT, combining current PDT market and a portion of cryotherapy market.)

Key Players & Entities

• Biofrontera Inc. (company) — Registrant and issuer of securities
• Prof. Hermann Luebbert (person) — Chairman and Chief Executive Officer of Biofrontera Inc.
• McGuireWoods LLP (company) — Legal counsel for Biofrontera Inc.
• Biofrontera AG (company) — Former controlling shareholder and related party of Biofrontera Inc.
• Pelthos Therapeutics Inc. (company) — Acquirer of Biofrontera's Xepi® product line
• FDA (regulator) — Approving body for pharmaceutical products
• Nasdaq Capital Market (regulator) — Stock exchange where BFRI is quoted
• Stephen E. Older, Esq. (person) — Legal counsel from McGuireWoods LLP
• Andrew J. Terjesen, Esq. (person) — Legal counsel from McGuireWoods LLP
• Daniel Hakansson (person) — Corporate Counsel for Biofrontera Inc.

FAQ

Risk Factors

• Patent Expiration and Generic Competition [high — legal]: Key patents for Ameluz® expired in 2019. While generic development has challenges, generic versions may enter the market, potentially forcing price reductions and significant market share loss.
• Dependence on Contract Manufacturers [high — operational]: The company relies on a single unaffiliated contract manufacturer for Ameluz® and has recently contracted a second. Failure to maintain these relationships or production issues at both could materially harm the business.
• Manufacturing Quality and Compliance [high — operational]: Failure to manufacture Ameluz®, RhodoLED® Lamps, or other products in sufficient quantities, at acceptable quality and cost, or to comply with cGMP, could lead to commercialization delays, inability to meet demand, and lost revenues.
• Product Liability and Patent Litigation [medium — legal]: The company has been and may continue to be involved in lawsuits related to patent protection and marketing of its products. These can be expensive, time-consuming, and unsuccessful.
• Reimbursement and Insurance Limitations [medium — market]: Limited or unavailable insurance coverage and medical expense reimbursement in certain market segments for Ameluz® and future indications could hinder product sales.
• Competition [high — market]: Biofrontera faces significant competition from other pharmaceutical and medical device companies, as well as existing treatments. Failure to compete effectively will negatively impact operating results.
• Regulatory Approvals and Reimbursement [high — regulatory]: The business is substantially dependent on Ameluz®. Failure to obtain and maintain regulatory approvals or reimbursement for existing and additional indications could materially harm the business.
• Healthcare Legislative Changes [medium — regulatory]: Changes in healthcare legislation could have a material adverse effect on the company's business and results of operations.

Industry Context

Biofrontera operates in the dermatology market, specifically focusing on photodynamic therapy (PDT) for actinic keratoses (AK). The AK treatment market is substantial, with an estimated 58 million Americans affected. While PDT currently holds a small market share (2%), Biofrontera aims to expand this by targeting a larger market size of $500 million, encompassing current PDT users and a portion of the cryotherapy market. Competition exists from other pharmaceutical companies and existing treatments.

Regulatory Implications

Biofrontera's business is heavily reliant on obtaining and maintaining regulatory approvals and reimbursement for its products, particularly Ameluz®. Failure in these areas, or adverse changes in healthcare legislation, could significantly impact its operations and financial performance. Compliance with cGMP is also a critical regulatory requirement for manufacturing.

What Investors Should Do

1. Monitor patent litigation and generic entry risks.
2. Track progress on new indications for Ameluz®.
3. Assess manufacturing and supply chain stability.
4. Evaluate the impact of the Xepi® divestiture and Ameluz® earnout structure.
5. Observe market adoption and reimbursement trends.

Key Dates

• 2019-12-31: Expiration of key patents for Ameluz® — Opens the door for potential generic competition, posing a risk to market share and pricing.
• 2021-10-31: FDA approval of RhodoLED® XL lamp — Expands the product portfolio and treatment options for photodynamic therapy.
• 2024-10-31: Increased Ameluz® dosage approved (one to three tubes) — Potentially enhances treatment efficacy and revenue per treatment.
• 2024-11-30: Supplemental New Drug Application for Ameluz® for superficial basal cell carcinoma submitted — Seeks to expand the approved indications for Ameluz®, increasing its market potential.
• 2025-06-01: Biofrontera assumed control of all Ameluz® clinical trials in the US — Aims for cost management and efficiency in clinical development.
• 2025-10-20: Acquisition of all US rights to Ameluz® and RhodoLED® from Biofrontera Group — Consolidates US rights and shifts from a transfer pricing model to an earnout structure.
• 2025-10-31: Divestiture of Xepi® product line — Focuses resources on core products and generates upfront cash and potential earnout revenue.
• 2025-12-02: Last Reported Sale Price of Common Stock — $0.81 per share, indicating a low current market valuation.

Glossary

Actinic Keratoses (AK)

Precancerous skin lesions caused by prolonged sun exposure. (The primary indication for Biofrontera's lead product, Ameluz®.)

Photodynamic Therapy (PDT)

A medical treatment that uses a drug (photosensitizer) and a specific wavelength of light to activate the drug, which then destroys targeted cells. (The therapeutic mechanism of Ameluz® and the core technology platform.)

Ameluz®

Biofrontera's flagship product, a topical gel used in PDT for the treatment of actinic keratoses. (The company's main revenue driver and focus of its commercial strategy.)

RhodoLED®

A medical device lamp used in conjunction with Ameluz® for PDT treatments. (A complementary product that enhances the Ameluz® treatment offering.)

cGMP

Current Good Manufacturing Practice; regulations enforced by the FDA to ensure product quality and safety. (Compliance is critical for manufacturing and commercialization of pharmaceutical products like Ameluz®.)

Earnout

A provision in a merger or acquisition agreement that allows the seller to receive additional compensation if certain future performance targets are met. (Describes the payment structure for US rights to Ameluz® and RhodoLED® acquired from Biofrontera Group.)

Supplemental New Drug Application (sNDA)

An application submitted to the FDA to propose changes to an approved drug product, such as new indications or dosage changes. (Biofrontera's submission for Ameluz® to treat superficial basal cell carcinoma.)

Selling Stockholders

Existing shareholders who are offering their shares for resale to the public, rather than the company itself issuing new shares. (The current S-1 filing involves the resale of shares by these stockholders; the company receives no proceeds.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of shares by selling stockholders and does not appear to be a direct comparison to a prior S-1 filing for the company itself. Key operational updates include the assumption of control over US clinical trials for Ameluz® effective June 1, 2024, and the acquisition of US rights to Ameluz® and RhodoLED® on October 20, 2025. The divestiture of Xepi® in Q4 2025 and the shift to an earnout model for Biofrontera Group payments are significant strategic changes. The last reported sale price of $0.81 on December 2, 2025, indicates a low current market valuation.

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferre
• $0.81 — price per share of our common stock was $0.81. The Selling Stockholders will offer
• $65.0 million — years when United States net sales are $65.0 million or less and an earnout of 15% in years
• $65.0 m — tates net sales of Ameluz ® exceed $65.0 million, continuing until the expiration
• $4 billion — market size is estimated to be roughly $4 billion for the three therapy types. Our primar
• $500 million — et, our targeted market is about 11% or $500 million of the total AK market (consisting of t
• $100 million — consisting of the current PDT market at $100 million and the portion of the market attribute
• $400 m — y treatments of more than 14 lesions at $400 million, assuming a tube price of $346).
• $346 — $400 million, assuming a tube price of $346). 6 In the third quarter of 2024, the
• $10,000,000 — (as defined in the APA) is a maximum of $10,000,000, payable as follows: 1) $3,000,000 in
• $3,000,000 — f $10,000,000, payable as follows: 1) $3,000,000 in cash, which was paid on the Closing
• $1,000,000 — other terms and conditions of the APA, $1,000,000 within thirty (30) days following the a
• $15,000,000 — 000,000 upon the initial achievement of $15,000,000 in annual net sales of the Product. 5

Filing Documents

• forms-1.htm (S-1) — 633KB
• ex5-1.htm (EX-5.1) — 29KB
• ex23-1.htm (EX-23.1) — 3KB
• ex107.htm (EX-FILING FEES) — 27KB
• forms-1_001.jpg (GRAPHIC) — 9KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• 0001493152-25-026443.txt ( ) — 832KB
• ex107_htm.xml (XML) — 6KB

RISK FACTORS

RISK FACTORS 9 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 13

USE OF PROCEEDS

USE OF PROCEEDS 14 DIVIDEND POLICY 14

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION 16 PRIVATE PLACEMENT OF THE PREFERRED STOCK 24 SELLING STOCKHOLDERS 24 PLAN OF DISTRIBUTION 25 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND MORE INFORMATION 26 INCORPORATION BY REFERENCE 26 i ABOUT THIS PROSPECTUS We and the Selling Stockholders have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We and the Selling Stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered by this prospectus, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We and the Selling Stockholders have not done anything that would permit the sale of our common stock being offered by the Selling Stockholders in any jurisdiction where action for that purpose is required, other than in the United relating to, the offering of the shares and the distribution of this prospectus outside the United States . BASIS OF PRESENTATION As used in this prospectus, unless the context otherwise requires, references to “we,” “us,” “our,” the “Company,” “Biofrontera” and similar references refer to Biofrontera Inc. which includes its wholly owned subsidiary Biofrontera Discovery GmbH. References in this prospectus to the “ Biofrontera Group ” (a related party) refer to Biofrontera AG and its consolidated subsidiaries, Biofrontera Pharma

Risk Factors

Risk Factors Investing in our common stock involves substantial risk. Our ability to execute our strategy is also subject to certain risks. The risks described under the heading “Risk Factors” included elsewhere in this prospectus and in our most recent Annual Report on Form 10-K, which is incorporated by reference herein, may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the most significant challenges and risks include the following: Certain important patents for our product Ameluz ® expired in 2019. Although the process of developing generic topical dermatological products for the first time presents specific challenges that may deter potential generic competitors, generic versions of Ameluz ® may enter the market following the recent expiration of these patents. If this happens, we may need to reduce the price of Ameluz ® significantly and may lose significant market share. Our business depends substantially on the success of our principal product Ameluz ® . If we are unable to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz ® for existing and additional indications, our business may be materially harmed. We currently depends on a single unaffiliated contract manufacturer to manufacture Ameluz ® and have recently contracted with a second unaffiliated contract manufacturer to begin producing Ameluz ® . If we fail to maintain its relationships with these manufacturers or if both of these manufacturers are unable to produce product for us, our business could be materially harmed. If we, or our manufacturing partners, as applicable, fail to manufacture Ameluz ® , RhodoLED ® Lamps or other marketed products in sufficient quantities and at acceptable quality and cost levels, or to fully comply with current good manufacturing practice, or cGMP, or other applicable manufacturin

View Full Filing

View this S-1 filing on SEC EDGAR